Literature DB >> 6386585

Ciglitazone, a new hypoglycaemic agent. 4. Effect on pancreatic islets of C57BL/6J-ob/ob and C57BL/KsJ-db/db mice.

A R Diani, T Peterson, G A Sawada, B M Wyse, B J Gilchrist, A E Hearron, A Y Chang.   

Abstract

Pancreases of treated and control male C57BL/6J-ob/ob and C57BL/KsJ-db/db mice were evaluated by qualitative and morphometric microscopic techniques to determine the effects of chronic ciglitazone treatment on the morphology of beta cells and surface area and number of pancreatic islets. The beta cells of treated ob/ob and db/db mice displayed moderate to heavy granulation whereas most beta cells of untreated obese and diabetic mice were extensively degranulated. Although moderate proliferation of the rough endoplasmic reticulum and Golgi apparatus was evident in some beta cells of treated db/db mice, both groups of treated ob/ob and db/db mice displayed an improved pattern of insulin synthesis and storage. In contrast, the beta cells of untreated ob/ob and db/db mice were in a severe state of stress which was indicated by extensive hypertrophy of the rough endoplasmic reticulum, Golgi apparatus and mitochondria. Some beta cells of untreated db/db mice also displayed lysosome aggregates indicative of early stages of necrosis. Morphometric analysis revealed that the surface area of islets of treated ob/ob mice was significantly smaller in comparison with that of untreated ob/ob mice. Since the surface area of islets of treated C57BL/6J-+/? mice (lean littermates of ob/ob mice) was less than that of treated ob/ob mice, the progression of islet hypertrophy in the obese mice was probably arrested or attenuated but not to the level of the treated +/? mice. The number of pancreatic islets was significantly greater in treated than in untreated db/db mice. A majority of the islets of untreated db/db mice were atrophic and consisted of acinar and endocrine cells whereas most of the islets of treated db/db mice appeared to be intact and unremarkable. The results of this study suggest that ciglitazone is an effective hypoglycaemic agent which may directly or indirectly promote beta-cell regranulation and an improved pattern of insulin synthesis and storage in ob/ob and db/db mice. However, in treated db/db mice, there still was some evidence of stress in the beta cells. Overall, the prolonged treatment with ciglitazone also seemed to inhibit the hypertrophy of islets in ob/ob mice and protect the structural integrity and viability of islets in db/db mice.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6386585     DOI: 10.1007/bf00273811

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  19 in total

1.  The influence of genetic background on the expression of the obese (Ob) gene in the mouse.

Authors:  D L Coleman; K P Hummel
Journal:  Diabetologia       Date:  1973-08       Impact factor: 10.122

2.  The influence of genetic background on expression of mutations at the diabetes locus in the mouse. I. C57BL-KsJ and C57BL-6J strains.

Authors:  K P Hummel; D L Coleman; P W Lane
Journal:  Biochem Genet       Date:  1972-08       Impact factor: 1.890

3.  Amelioration of insulin resistance in obese mice.

Authors:  R J Mahler; O Szabo
Journal:  Am J Physiol       Date:  1971-10

4.  Studies in the diabetic mutant mouse. II. Electron microscopy of pancreatic islets.

Authors:  A A Like; W L Chick
Journal:  Diabetologia       Date:  1970-06       Impact factor: 10.122

5.  Studies of a simplified plasma insulin immunoassaay using cellulose powder.

Authors:  D S Zaharko; L V Beck
Journal:  Diabetes       Date:  1968-07       Impact factor: 9.461

6.  Insulin response in pancreatectomized dogs treated with oxytetracycline.

Authors:  N Hiatt; G Bonorris
Journal:  Diabetes       Date:  1970-05       Impact factor: 9.461

7.  Streptozotocin-induced diabetes in the Chinese hamster. Biochemical and endocrine disorders.

Authors:  A Y Chang; R E Noble; B M Wyse
Journal:  Diabetologia       Date:  1977-12       Impact factor: 10.122

8.  Alteration of islet cell populations in spontaneously diabetic mice.

Authors:  D Baetens; Y Stefan; M Ravazzola; F Malaisse-Lagae; D L Coleman; L Orci
Journal:  Diabetes       Date:  1978-01       Impact factor: 9.461

9.  Ciglitazone, a new hypoglycaemic agent. 3. Effect on glucose disposal and gluconeogenesis in vivo in C57BL/6J-ob/ob and -+/? mice.

Authors:  A Y Chang; B J Gilchrist; B M Wyse
Journal:  Diabetologia       Date:  1983-12       Impact factor: 10.122

10.  Ciglitazone, a new hypoglycemic agent. II. Effect on glucose and lipid metabolisms and insulin binding in the adipose tissue of C57BL/6J-ob/ob and -+/? mice.

Authors:  A Y Chang; B M Wyse; B J Gilchrist
Journal:  Diabetes       Date:  1983-09       Impact factor: 9.461

View more
  4 in total

1.  Ultra-structural study of insulin granules in pancreatic β-cells of db/db mouse by scanning transmission electron microscopy tomography.

Authors:  Yanhong Xue; Wei Zhao; Wen Du; Xiang Zhang; Gang Ji; Wang Ying; Tao Xu
Journal:  Protein Cell       Date:  2012-07-10       Impact factor: 14.870

2.  Sex dimorphic actions of rosiglitazone in generalised peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-deficient mice.

Authors:  S Z Duan; M G Usher; E L Foley; D S Milstone; F C Brosius; R M Mortensen
Journal:  Diabetologia       Date:  2010-04-17       Impact factor: 10.122

3.  Inhibition of human insulin gene transcription by peroxisome proliferator-activated receptor gamma and thiazolidinedione oral antidiabetic drugs.

Authors:  S Schinner; R Krätzner; D Baun; C Dickel; R Blume; E Oetjen
Journal:  Br J Pharmacol       Date:  2009-03-26       Impact factor: 8.739

4.  Proinsulin misfolding is an early event in the progression to type 2 diabetes.

Authors:  Anoop Arunagiri; Leena Haataja; Anita Pottekat; Fawnnie Pamenan; Soohyun Kim; Lori M Zeltser; Adrienne W Paton; James C Paton; Billy Tsai; Pamela Itkin-Ansari; Randal J Kaufman; Ming Liu; Peter Arvan
Journal:  Elife       Date:  2019-06-11       Impact factor: 8.140

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.